Ricardo Rivas
Medical · Temecula, CANPI 1437581774
Payments from drug & device makers
Across 158 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$757
- AbbVie$609
- Novo Nordisk$278
- Lilly USA, LLC$225
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$204
- AstraZeneca$127
- plus $826 from 24 others
What the payments were for
- Food & beverage$3,026100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 38 | $757 |
| AbbVie | 38 | $609 |
| Novo Nordisk | 10 | $278 |
| Lilly USA, LLC | 11 | $225 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $204 |
| AstraZeneca | 7 | $127 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Abbott | 3 | $67 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Biosense Webster, Inc. | 2 | $55 |
| Novartis | 3 | $50 |
| Genentech USA, Inc. | 2 | $47 |
| Boehringer Ingelheim | 2 | $41 |
| Pfizer | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $37 |
| Seqirus USA Inc | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| CMP Pharma, Inc. | 1 | $29 |
| Dexcom, Inc. | 1 | $29 |
| Merck | 1 | $22 |
| Exact Sciences | 1 | $22 |
| GSK | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $15 |
| Mannkind Corporation | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,026 in reported general payments places this provider in the 80th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $50,611 |
| JardianceEmpagliflozin | 66 | $49,686 |
| OzempicSemaglutide | 52 | $47,205 |
| XifaxanRifaximin | 13 | $46,385 |
| MounjaroTirzepatide | 42 | $44,794 |
| RybelsusSemaglutide | 33 | $38,541 |
| LinzessLinaclotide | 48 | $33,516 |
| FarxigaDapagliflozin Propanediol | 25 | $31,102 |
| XareltoRivaroxaban | 20 | $23,955 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $20,673 |
| TrulicityDulaglutide | 21 | $19,646 |
| NexletolBempedoic Acid | 29 | $18,040 |
| Repatha SureclickEvolocumab | 29 | $16,492 |
| Victoza 3-PakLiraglutide | 15 | $13,300 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 329 | $9,461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $278 | $85,74685 claims |
| Lilly USA, LLCMounjaro, Trulicity | $225 | $64,44063 claims |
| PfizerEliquis | $41 | $50,61165 claims |
| Boehringer IngelheimJardiance | $41 | $49,68666 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $204 | $46,38513 claims |
| AbbVieLinzess | $609 | $33,51648 claims |
| AstraZenecaFarxiga | $127 | $31,10225 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $20 | $28,06459 claims |
| Johnson & JohnsonXarelto | $37 | $23,95520 claims |
| Esperion Therapeutics, Inc.Nexletol | $75 | $18,04029 claims |
| MerckBelsomra | $22 | $6,03914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 medical providers in California.
Other medical in Temecula
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.